Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australia has led the world in the research and development of this scan using a relatively novel radiotracer, known as PSMA PET/CT. The availability of funding for PSMA PET/CT scans is a major win for patients, who until now have either paid for these tests themselves or found the scans unobtainable because of the cost. The Australasian Association of Nuclear Medicine Specialists (AANMS) welcomed the MBS funding which it says will help improve outcomes for thousands of men with a higher risk prostate cancer. “PSMA PET/CT imaging enables highly specific detection of tumour sites throughout the body with far greater sensitivity compared to other conventional scans. This enables doctors to make more accurate
diagnoses than is currently possible with other MBS-funded scans, and which in turn can be lifesaving for some patients,” said AANMS President, Associate Professor Sze Ting Lee.
The AANMS has worked closely with partners to achieve this important milestone in the diagnosis and treatment of prostate cancer.
“We would like to acknowledge the work of Dr Robert Ware from Cyclotek in generating the original funding application and their ongoing support in steering the application with AANMS during the tenure of my predecessor, Dr Geoff Schembri. We also extend our thanks to all those who supported the application, including AstraZeneca who sponsored the submission,” Associate Professor Lee said.
With funding now available, AANMS will work closely with other key stakeholders to ensure that patients are appropriately referred for these tests.
Australian Health Journal spoke with Associate Professor Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
About AANMS
The AANMS is a peak body representing medical practitioners working in the field of nuclear medicine diagnosis and therapy. It works to promote and advance the clinical practice of nuclear medicine, which can be used to both diagnose and treat patients with a range of health conditions including the leading causes of death in Australia; cancer, dementia, heart and lung diseases; as well as renal, endocrine and paediatric disorders. Together with government and other stakeholders, AANMS is working to build a strong and sustainable nuclear medicine sector in Australia in order to optimise health outcomes for Australia patients.
-
Australia’s Nursing Crisis Snapshot
“Nursing, already under pressure, is reaching breaking point due to the pressures of COVID-19 and a disjointed healthcare system, including the acute, primary and aged care sectors”, says Kylie Ward, Australian College of Nursing CEO adding, “We must act now to protect our nurses and healthcare; the time has come for a national reckoning on nursing in Australia.”
Australian nurses cannot continue to work under the extreme pressure they are currently operating under – the impacts are mounting.
The almost 400,000 Australian nurses are a constant presence in every one of our major life milestones, national emergencies and global crises. The nurse of today holds a science degree, possesses highly technical training, valuable medical opinions, front-row expertise, is an effective trainer, and is skilled in population and systemic thinking. But the pandemic is inflicting a major emotional and physical toll on nurses.
In this “Perspectives” special, Australian Health Journal spoke with 4 nurses on the challenges they or nurses in their circle have experienced, the key issues as well some of the opportunities. These nurses come from national leadership & policy, large scale workforce management, a final year student completing over a year on placement across 6 Melbourne Hospitals and a NSW based ICU nurse stranded in Mexico, unable to return to a critical role in nursing to an already strained team due to incoming quotas.
While the issues are challenging, there are strategies that can be put into place to ease the pressure, to support nurses, and nursing care in Australia. These are discussed by the the 4 nurses.
– Adjunct Professor Kylie Ward FACN CEO, Australian College of Nursing
– Adjunct Professor Alanna Geary FACN ACN Chair of Workforce Sustainability Policy Chapter & Chief Nursing & Midwifery Officer, Metro North Health
– Natalie Reyes, NSW based ICU Nurse Currently stranded in Mexico
– Hayley Pollock, Final Year Bachelor of Nursing Student & ACN Emerging Nurse Leader
-
Australian Healthcare Week 2019: Pitch Fest Finalist Lumin
Startup company Lumin was a Pitch Fest Finalist at last week’s Australian Healthcare Week Expo in Sydney. The Lumin platform is used in aged care where loneliness and isolation can be a trigger for stroke and dementia. Lumin helps the connection to care providers, family members and duress monitoring services in a device that has been designed for those with dementia, vision impairment or find complex devices difficult to use.
Managing Director and Co-Founder Paul Wilson spoke at the Mepacs booth with Anne Dao from Australian Health Journal about the market they target and the design of the user experience, including the remote servicing and monitoring. The integration allows the monitoring team in the call centre see and hear the personal raising the alarm. Mepacs is a provider of personal duress alarms and have teamed up with Lumin.
-
Inaugural vaccine value chain conference talks about Team Australia
For the first time, key decision-makers and thought leaders from government, industry, academia, NGOs, and representatives from the immunisation community converged in a 2 day conference in Sydney hosted by Biointelect, highlighting the transformative potential of collaborative innovation.
